Daxor Corporation Common Stock
DXR Real Time Price USDRecent trades of DXR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by DXR's directors and management
Government lobbying spending instances
-
$20,000 Jan 20, 2023 Issue: Defense
-
$10,000 Oct 17, 2022 Issue: Defense
-
$30,000 Jul 19, 2022 Issue: Defense
-
$20,000 Oct 12, 2017 Issue: Defense Veterans
-
$10,000 Jul 14, 2017 Issue: Veterans Defense
-
$10,000 Apr 19, 2017 Issue: Defense Veterans
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Blood volume analyzer with guidance Jan. 02, 2024
-
Patent Title: Remote blood volume monitor Oct. 31, 2023
-
Patent Title: Blood volume analysis with volume-aware blood component measures and treatment Dec. 21, 2021
-
Patent Title: Automated blood analyzer Apr. 07, 2015
-
Patent Title: Automated total body albumin analyzer Apr. 07, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of DXR in WallStreetBets Daily Discussion
Recent insights relating to DXR
Recent picks made for DXR stock on CNBC
ETFs with the largest estimated holdings in DXR
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DXR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.